Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Nature Medicine, Год журнала: 2024, Номер 30(8), С. 2208 - 2215

Опубликована: Июнь 2, 2024

Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated and safety analyses, including secondary exploratory endpoints 41 months) of DESTINY-Breast03. Patients with advanced HER2-positive metastatic breast cancer previously treated taxane were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 (263 patients)). The primary endpoint was progression-free survival (PFS) by blinded independent central review reported. key overall (OS). Other included objective response rate, duration PFS (all investigator assessment) safety. At data cutoff, 20 November 2023, median assessment 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24-0.38), the 36-month rate 45.7% 12.4% OS 52.6 42.7 (HR, 0.73; CI, 0.56-0.94) T-DM1, respectively. Treatment-emergent adverse events consistent previous analyses. No new instances grade ≥3 interstitial lung disease pneumonitis occurred 16.7% 3.4% (T-DM1)). With longer continued demonstrate superior a manageable profile. ClinicalTrials.gov registration: NCT03529110 .

Язык: Английский

---

Expression Patterns of Matricellular Proteins in Metastatic Breast Cancer at the Background of Metabolic Syndrome

Experimental Oncology, Год журнала: 2025, Номер 46(4), С. 333 - 340

Опубликована: Фев. 20, 2025

Background. Metastatic breast cancer (mBCa) is one of the main causes mortality among postmenopausal women with malignant neoplasms. Numerous studies indicate feasibility using bone matrix remodeling proteins to predict BC course. Aim. To investigate relationship between osteopontin (OPN) and osteonectin (ON) expression levels in tumor tissue patients menopausal age primary mBCa (pmBCa) metabolic syndrome (MetS) taking into account clinicopathological features disease. Materials Methods. The study included 54 pmBCa, 23 from whom had manifestations MetS, while 31 were without MetS. matricellular (OPN ON) was determined immunohistochemically. Results. In MetS pmBCa category N3, an increase level OPN (H-Score 265.6 ± 7.7, p < 0.05) recorded along a decrease ON 123.2 0.05). invasive lobular characterized by significant ( H-Score 219.4 8.4) 144.8 7.5). (p luminal A, B, Her2/neu subtypes H-Scores 140.2 7.8, 119.3 10.2, 110.0 respectively). Among cases diagnosed metastatic liver disease, lower 146.2±9.1). Conclusions. obtained data demonstrated indicators degree malignancy indicated prospects for further their prognostic value presence

Язык: Английский

---

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape

Current Oncology Reports, Год журнала: 2024, Номер 26(8), С. 890 - 903

Опубликована: Июнь 1, 2024

Abstract Purpose of Review Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic active management cancer. This review evaluates HRD testing the therapeutic implications in a global context. Recent Findings Ongoing research efforts have highlighted importance beyond BRCA1/2 as potential target However, despite improved affordability next-generation sequencing (NGS) discovery PARP inhibitors, economic geographical barriers access to screening do not allow all patients benefit from personalized treatment approach they provide. Summary Advancements modalities targeted therapeutics enable tailored management. inequalities optimized treatments are contributing widening health disparities globally.

Язык: Английский

---

Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer

Cancer Science, Год журнала: 2024, Номер 115(9), С. 3079 - 3088

Опубликована: Июль 9, 2024

Abstract The global phase 3 DESTINY‐Breast03 study ( ClinicalTrials.gov ; NCT03529110) showed statistically significant and clinically meaningful improvements in progression‐free survival (PFS) overall (OS) with trastuzumab deruxtecan (T‐DXd) over emtansine (T‐DM1) patients human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (mBC) previously treated a taxane. Here, we report subgroup analysis of Asian enrolled DESTINY‐Breast03. In total, 309 (149 the T‐DXd arm 160 T‐DM1 arm) from countries regions were randomized. At data cutoff (July 25, 2022), median duration follow‐up subpopulation was 29.0 months 26.0 T‐DM1. PFS (determined by blinded independent central review) hazard ratio 0.30 (95% confidence interval 0.22–0.41) favoring (median 25.1 vs. 5.4 months). Median OS not reached 37.7 arm. treatment 15.4 5.5 incidence grade ≥3 drug‐related treatment‐emergent adverse events similar between both arms (49.0% 46.5%) consistent population. Adjudicated interstitial lung disease or pneumonitis occurred 12.9% 2.5% T‐DM1, higher Japanese patients; none these ≥4 events. These efficacy safety reinforce favorable benefit–risk profile HER2‐positive mBC, including subgroup.

Язык: Английский

---

Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial

Nature Medicine, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Язык: Английский

---

Retrospective Comparative Survival Analysis of Ablation Plus Systemic Therapy versus Systemic Therapy Alone for Breast Cancer Liver Metastases, Stratified by Extrahepatic Metastases Status

The Breast, Год журнала: 2025, Номер 79, С. 103876 - 103876

Опубликована: Янв. 9, 2025

Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially patients combined with extrahepatic metastases. To assess whether plus systemic therapy (AS) improves survival outcomes in BCLM compared to alone. This retrospective study analyzed who received either AS or Propensity score matching (PSM) and analysis were performed, taking into account factors like characteristics primary cancer, therapies received. The included 1021 female patients, a median follow-up 39.6 months. Of these 132 underwent 836 After PSM, among (≤3 tumors, each ≤3 cm), overall (OS) those treated alone was 65.5 40.4 months, respectively (HR = 0.48, p .003); subset metastases, OS 46.4 40.8 0.58, .047). Among >3 cm lesions, 45.2 29 0.67, .084). provide longer alone, even For larger more numerous (>3 lesions), may benefit, but further validation is needed.

Язык: Английский

---

Long-Term Survival of Metachronous Isolated Adrenal Metastasis in Luminal Breast Cancer: A Case Report and Literature Review

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Янв. 28, 2025

Metachronous metastasis occurs many years later in cases of hormone-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, with the most common sites being lymph nodes, bones, liver, lungs, and brain. The late recurrence estrogen (ER)-positive cancer is attributed to prolonged adjuvant therapy high expression dormancy-associated genes, allowing cells survive for decades without proliferating. It a form chronic that remains asymptomatic, no clinical signs progression or recurrence. Estrogen receptor-negative cancers, on other hand, have long-term tumor dormancy due their fast low dormancy-related genes. Adrenal gland metastasis, particularly as an oligometastatic presentation, exceedingly rare, optimal treatment strategies remain elusive. In this report, we present case demonstrating survival after adrenal accompanied by comprehensive literature review. At age 48, our patient was diagnosed invasive ductal carcinoma left breast. Treatment included breast-conserving surgery, radiotherapy, hormone therapy. Ten later, she developed solitary metastasis. laparoscopic adrenalectomy change hormonal Our currently still asymptomatic evidence disease. Her overall over 20 exceptional. Resection combined systemic represents recommended approach metachronous contemporary context, antihormonal combination CDK4/6 inhibitors should be considered. underscores necessity establishing lifelong (inter)national registry document rare recurrences systematically. Such would provide insights into prevalence uncommon scenarios offer invaluable data proposed treatments, facilitating development uniform strategies.

Язык: Английский

---

ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 16, 2025

Язык: Английский

---

Quality of Life After Locoregional Treatment in Women with De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Cancers, Год журнала: 2025, Номер 17(5), С. 751 - 751

Опубликована: Фев. 22, 2025

Primary site locoregional treatment (LRT) of metastatic breast cancer has been performed and evaluated with the aim to improve survival, prevent complications, alleviate local symptoms. As some studies fail show a survival benefit, quality life is important consider when deciding on LRT. The this study was evaluate quantify impact LRT patients de novo (dnMBC) through systematic review literature meta-analysis. Multiple databases were searched May 2024 following keywords: (i) dnMBC; (ii) LRT, including surgery +/- radiotherapy; (iii) QOL. Six included in qualitative synthesis four meta-analysis (481 women, n = 251 230 control groups). There significant QOL decrease group at 18 months (standardized mean difference [SMD] -0.63; 95% confidence interval [CI] -0.98--0.26; p < 0.001, low heterogeneity I2 33%) after 30 (SMD -0.82; 95%CI -1.58--0.06; 0.034, high 93%), while no statistically observed short term (6 months, 0.333). This shows that there lacking evidence regarding benefits population, even numerical deterioration global several treatment. Future ongoing research may provide additional insights into question dnMBC specifics subgroups.

Язык: Английский

---

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 25, 2025

We investigated whether TK1 concentration or activity in the blood, drawn at baseline and under therapy, might have value for therapy management 110 hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) patients treated with CDK4/6 inhibitors (CDK4/6i) and/or endocrine (ET). were not significantly correlated each other matched samples. In CDK4/6i cohort baseline, high associated a decreased PFS primary resistance. Longitudinal sampling revealed higher variability of compared to that was reduced during therapy. Elevated after six months an increase from PFS. These results indicate possible before HR+/HER2- mBC guide treatment warrants further investigation.

Язык: Английский

---